AI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunity

The post AI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunity appeared first on 24/7 Wall St..

Artificial intelligence is reshaping nearly every industry, but some of its biggest opportunities are emerging far from Silicon Valley. Biotechnology has spent decades producing breakthrough medicines, yet drug development has remained painfully slow, often taking 10 to 15 years while roughly 90% of candidates never reach approval.

AI is beginning to change that equation. By treating drug discovery as a massive optimization problem, AI can analyze millions of molecular combinations in weeks instead of years, dramatically shortening the path from concept to clinical testing. Few areas stand to benefit more than peptide-based medicines.

These short chains of amino acids occupy a sweet spot between traditional small-molecule drugs and complex biologics. Better yet, their modular design makes them exceptionally well suited for AI-driven discovery. For investors, that combination could create one of biotech’s most compelling long-term growth opportunities.

Why Peptides Are a Natural Fit for AI

Developing conventional small-molecule drugs is often a balancing act. Improving one characteristic — such as potency, stability, or solubility — can easily compromise another.

Peptides are far more flexible. Because they’re built from amino acid building blocks, researchers can modify them with remarkable precision, almost like editing lines of computer code. That makes them an ideal playground for machine learning algorithms.

AI models can rapidly search enormous chemical libraries, predict how peptides will fold, estimate their stability, identify promising drug targets, and forecast how they’ll behave inside the human body. Work that once demanded years of laboratory trial and error can now be completed computationally in a fraction of the time.

Manufacturing and delivery have historically limited broader adoption of peptide drugs, but AI is helping overcome many of those challenges by designing molecules that are easier to produce and more effective.

The commercial results are already becoming apparent. Eli Lilly (NYSE:LLY) has increasingly integrated AI into candidate selection across its metabolic disease pipeline, where peptide therapies play a central role. The company’s tirzepatide franchise — Mounjaro and Zepbound — generated $36.5 billion in revenue during 2025, a 215% increase from the prior year. By comparison, Novo Nordisk‘s (NYSE:NVO) comparable GLP-1 peptide portfolio — Ozempic and Wegovy — grew 39% to $34.6 billion over the same period.

Turning a 90% failure rate into a multi-billion dollar optimization game. The biotech gold rush is moving from the lab to the motherboard. © 24/7 Wall St.

AI Is Accelerating the Next Generation of Medicines

Peptide drugs have already transformed the treatment of diabetes, obesity, and several forms of cancer. AI is now expanding what’s possible.

Researchers are designing entirely new classes of peptides containing non-natural amino acids that resist degradation, remain active for weeks instead of hours, and target diseased tissue with far greater precision.

For investors, established pharmaceutical leaders like Lilly remain the safest way to capitalize on this trend. It trades at a forward P/E of roughly 33, while Novo Nordisk traded around 16. Both companies generate billions in annual cash flow that can fund continued research, commercialization, and pipeline expansion. Lilly alone produced $16.8 billion in operating cash flow during 2025, a 91% increase from the previous year.

Beyond the pharmaceutical giants, investors can also gain exposure through companies building the AI infrastructure behind drug discovery.

Schrodinger (NASDAQ:SDGR) develops physics-based molecular simulation software used by 18 of the world’s 20 largest pharmaceutical companies. The company reported 12% revenue growth during the first quarter of 2026.

Meanwhile, Recursion Pharmaceuticals (NASDAQ:RXRX) generated $66.4 million in trailing-12-month revenue, supported by multiple AI-powered research partnerships spanning peptides and other therapeutic platforms.

While AI is also improving cell-based therapies such as CAR-T, peptide medicines may reach patients more quickly thanks to simpler manufacturing processes and easier administration.

Key Takeaway

Artificial intelligence won’t eliminate the risks of drug development, but it is steadily improving the odds.

For peptide medicines, AI is enabling faster discovery, more accurate molecular design, and therapies that were previously impossible to create. That combination could significantly accelerate innovation across some of medicine’s largest markets.

For most investors, the best starting point remains established leaders like Eli Lilly and Novo Nordisk, whose proven peptide franchises and robust cash generation provide a measure of stability while AI expands future opportunities. Investors seeking greater upside can complement those holdings with AI-focused platforms such as Schrodinger or Recursion Pharmaceuticals.

Clinical setbacks and premium valuations remain important risks, so diversification is essential. But as AI continues to compress years of research into months of computation, peptide drugs may become one of the clearest examples of how artificial intelligence creates value far beyond the technology sector itself. 

For patient investors, this convergence could represent one of biotech’s most exciting growth stories over the coming decade.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Eli Lilly didn’t make the cut. Grab the names FREE today.

The post AI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunity appeared first on 24/7 Wall St..